Haematological Malignancies

The investigation of haematological malignancies (cancers of the blood, bone marrow and lymph nodes) represents a significant area of clinical and research activity. Our understanding of how and why blood cancers develop is underpinned by basic research into how blood cells develop normally and what happens at the earliest stage of malignancy. Research is closely aligned with clinical treatment so that patients receive the best diagnostic and therapeutic options based on their particular cancer.

Blood cancer research in Cambridge

Programme Contacts

University of Cambridge
Department of Haematology
University of Cambridge
Department of Haematology

Selected publications

Centre for Blood and Leukemia Research

There are currently 13 group leaders, many of whom are clinically qualified, working together as part of this consortium. Their research is focused on studying novel therapeutic strategies based on epigenetic regulation, mechanisms of transcriptional and translational dysregulation, novel diagnostic tools, and other aspects of regulation in haematological malignancies. These investigators include many groups across the Cambridge Cancer Centre including the Cambridge Institute for Medical Research, the Wellcome Trust Sanger Institute and the MRC Laboratory of Molecular Biology.

Integrating the lab and the clinic

Myeloproliferative disorders are a group of diseases in which the bone marrow makes too many red blood cells, white blood cells, or platelets. Researchers have discovered that many people with these disorders have a particular genetic mutation affecting an enzyme, called JAK2. This enzyme has an important role for carrying messages within cells but, in the case of these disorders, the mutation causes too many new blood cells to be produced. The finding means that patients can be offered different treatment depending on whether or not their disease has been caused by the mutation.

Cambridge Blood and Stem Cell Biobank

The Cambridge Blood and Stem Cell Biobank is a tissue bank housing samples from both patients with haematological malignancies and normal individuals. Over 4,000 blood and bone marrow-derived samples from patients with haematological malignancies and around 500 healthy samples have been collected. The biobank processes cells, proteins, nucleic acids and serum from the samples for use in world leading laboratory and clinical research.

Testing new drug combinations

A large clinical trial of over 1,000 patients with a myeloproliferative disorder called essential thrombocythaemia is taking place to assess the efficiency of different combinations of drug treatment.

Molecular histopathology

The Division of Molecular Histopathology at Addenbrooke's Hospital is a national referral centre for haematological malignancies. This service is being expanded to provide next generation DNA sequencing for both haematological and epithelial cancers. This will support the testing of circulating tumour DNA (ct DNA) in patients using novel sequencing strategies.

Principal investigators and consultants

  • All members
  • Group leaders
  • Clinical consultants
University of Cambridge
Department of Haematology
Using a novel proteomic technique, plasma membrane profiling, we aim to determine the cell surface proteome of myeloma cell lines, as well...
PI:
N
CC:
N
University of Cambridge
Department of Haematology
The Cambridge Blood and Stem Cell Biobank is a facility of over 6000 viable and nucleic acid samples, the majority from patients with...
PI:
Y
CC:
N
University of Cambridge
Department of Haematology
Wellcome Trust MRC Cambridge Stem Cell Institute
I focus my research in the study of the transcriptional networks that control stem cell differentiation and how their perturbation can lead...
PI:
N
CC:
N
Wellcome Trust Sanger Institute
Cancer Genetics and Genomics
Dr Peter Campbell is Head of Cancer Genetics and Genomics at the Institute and is joint head of the Cancer Genome Project. His research...
PI:
Y
CC:
Y
University of Cambridge
Department of Haematology
National Blood Service
Our long-term aim is to understand the interplay between the myriad pathways involved in the pathogenesis of multiple myeloma so that these...
PI:
Y
CC:
Y
Cambridge University Hospitals NHS Foundation Trust
(tbc)
PI:
N
CC:
Y
Cambridge University Hospitals NHS Foundation Trust
Department of Haematology
.
PI:
N
CC:
Y
Department of Haematology
Wellcome Trust MRC Cambridge Stem Cell Institute
(tbc)
PI:
N
CC:
N
University of Cambridge
Department of Pathology
Lymphomas are a group of highly heterogeneous tumors derived from B or T lymphocytes and occur at both nodal and extranodal sites. The...
PI:
Y
CC:
Cambridge University Hospitals NHS Foundation Trust
Department of Haematology
.
PI:
N
CC:
Y
Cambridge University Hospitals NHS Foundation Trust
Department of Haematology
My laboratory research focuses on transcriptional regulation and chromatin structure. I maintain a supervisory role for a research...
PI:
N
CC:
Y
Babraham Institute
Nuclear Dynamics Programme
Nuclear Organization and genome function.
PI:
Y
CC:
University of Cambridge
Department of Haematology
Wellcome Trust MRC Cambridge Stem Cell Institute
The Göttgens group uses a combination of experimental and computational approaches to study how transcription factor networks control the...
PI:
Y
CC:
Cambridge University Hospitals NHS Foundation Trust
Department of Pathology
.
PI:
N
CC:
Y
University of Cambridge
Department of Haematology
Cambridge Institute for Medical Research, Wellcome Trust MRC Cambridge Stem Cell Institute
The JAK/STAT pathway has essential roles in several aspects of metazoan biology including haematopoiesis and stem cell function. Somatic...
PI:
Y
CC:
Y
University of Cambridge
Cancer Research UK Cambridge Institute
Flow cytometry core facility
PI:
N
CC:
N
University of Cambridge
Department of Haematology
Cambridge Institute for Medical Research
Our aim is to further characterise the molecular and cellular biology of cancer stem cells and to compare and contrast these to normal stem...
PI:
Y
CC:
Y
University of Cambridge
Department of Pathology
PI:
N
CC:
N
University of Cambridge
Department of Haematology
Wellcome Trust MRC Cambridge Stem Cell Institute
My research focuses on normal and malignant blood stem cell biology.  Specifically, I am interested in understanding stem cell...
PI:
Y
CC:
N
University of Cambridge
Department of Biochemistry
I try to understand the oncogenic activity of c-Myc and its interplay with other oncogenes such as Ras or Wnt1. To this end we use a number...
PI:
Y
CC:
N
Cambridge University Hospitals NHS Foundation Trust
Department of Haematology
.
PI:
N
CC:
Y
University of Cambridge
Department of Haematology
Daily blood cell production is guaranteed throughout life by a hierarchy with haematopoietic stem cells (HSC) at its root. HSC are very...
PI:
Y
CC:
N
Wellcome Trust Sanger Institute
Wellcome Trust Sanger Institute
Dr. Liu?s laboratory is working on several research areas: mouse genetics, stem cells, development and cancer. His lab discovered a new...
PI:
Y
CC:
University of Cambridge
Department of Pathology
Our research focusses on dissecting mechanisms of lymphomagenesis using anaplastic large cell lymphoma (ALCL) as our working model. ALCL is...
PI:
N
CC:
N
University of Cambridge
Department of Physiology, Development and Neuroscience
PI:
Y
CC:
Department of Haematology
PI:
N
CC:
N
University of Cambridge
Department of Haematology
Wellcome Trust MRC Cambridge Stem Cell Institute
NHS-Blood and Transplant
The Méndez-Ferrer laboratory research focuses on the regulation of the haematopoietic stem-cell niche in health and disease. Blood stem...
PI:
N
CC:
N
University of Cambridge
Department of Genetics
Cambridge Computational Biology Institute (CCBI)
My group uses computational and experimental methods to investigate basic biological processes. We also build databases to exploit the...
PI:
Y
CC:
University of Cambridge
Department of Pathology
Characterisation of the genetic landscape in MALT lymphomas MALT (Mucosa Associated Lymphoid Tissue) lymphoma is an indolent B cell...
PI:
N
CC:
N
AstraZeneca
Early Drug Development Phase 1 studies First in human studies Cancer
PI:
N
CC:
N
University of Cambridge
Department of Pathology
Division of Molecular Histopathology
Recently cancer stem cells have been described which are responsible for the continued growth and propagation of malignancies. This cell...
PI:
N
CC:
University of Cambridge, Babraham Institute
Department of Pathology
Phosphoinositide 3-kinases (PI3Ks) are enzymes that act downstream of tyrosine kinase signalling and generate second messenger signalling...
PI:
Y
CC:
N
Wellcome Trust Sanger Institute
Virus genomics
Genomics of the oncogenic viruses Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus and their associated tumours.
PI:
N
CC:
N
University of Cambridge
Department of Haematology
We aim to understand the role of transcriptional noise in normal and malignant cell fate decisions, and to explore candidate noise...
PI:
Y
CC:
N
University of Cambridge
Department of Pathology
Role of Fbxo7 in haematopoisis and oncogenesis.
PI:
N
CC:
University of Cambridge, Cambridge University Hospitals NHS Foundation Trust
Department of Haematology
We study the interaction between malignant B cells and cells of the microenvironment to understand signalling pathways mediating the...
PI:
Y
CC:
Y
The central aim of this PhD project is to characterise alterations in the niche of HSC, imposed by malignant B cells, and to understand...
PI:
N
CC:
N
Wellcome Trust Sanger Institute
Haematological Cancer Genetics Group
I am a Wellcome Trust Senior Clinical Fellow and head the Haematological Cancer Genetics Group at the Sanger Institute. My group is...
PI:
Y
CC:
Y
University of Cambridge
Department of Haematology
Cambridge Institute for Medical Research
Haematology
Our long-term goal is to elucidate the molecular mechanisms of ribosome assembly in eukaryotic cells and to understand how defects in this...
PI:
Y
CC:
Y
(tbc)
PI:
N
CC:
N
(tbc)
PI:
N
CC:
N